We are live on
!
Find out more
SC
Stempoint Capital Portfolio holdings
AUM
$581M
1-Year Est. Return
373.68%
This Fund
S&P 500
This Quarter
Est. Return
+35.11%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$58.2M
(+11%)
Cap. Flow
-$54.7M
Cap. Flow
% of AUM
-9.43%
Top 10 Holdings %
Top 10 Hldgs %
40.99%
Holding
116
New
34
Increased
19
Reduced
30
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tango Therapeutics
TNGX
|
+$25.3M |
| 2 |
Erasca
ERAS
|
+$19M |
| 3 |
Tyra Biosciences
TYRA
|
+$14.5M |
| 4 |
TRAX
First Tracks Biotherapeutics
TRAX
|
+$11.6M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$38.5M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$28.4M |
| 3 |
Revolution Medicines
RVMD
|
+$17.8M |
| 4 |
MBX
MBX Biosciences
MBX
|
+$14.9M |
| 5 |
Immunovant
IMVT
|
+$14.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.23% |
| 2 | Miscellaneous | 0.45% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CALL
AstraZeneca
AZN
$252B
| $180K | 0.03% |
+25,000
| New | +$4.7M |
|
77
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.6B
| $178K | 0.03% |
400,000
+250,000
| +167% | +$33.8M |
|
|
78
CALL
Tango Therapeutics
TNGX
$3.78B
| $175K | 0.03% |
+100,000
| New | +$2.47M |
|
|
79
PUT
Revolution Medicines
RVMD
$44.7B
| $128K | 0.02% |
30,000
-70,000
| -70% | -$10.2M |
|
|
80
PUT
Erasca
ERAS
$5.7B
| $90K | 0.02% |
+200,000
| New | +$2.86M |
|
81
PUT
ARK Genomic Revolution ETF
ARKG
$1.99B
| $75K | 0.01% |
+100,000
| New | +$3.18M |
|
82
PUT
Roivant Sciences
ROIV
$24.9B
| $40K | 0.01% |
+100,000
| New | +$2.96M |
|
83
VistaGen Therapeutics
VTGN
$11M
| $17.3K | ﹤0.01% |
616,749
| – | – |
|
84
PUT
Amgen
AMGN
$237B
| $15K | ﹤0.01% |
+15,000
| New | +$5.13M |
|
|
JBIO
85
Jade Biosciences
JBIO
$1.28B
| – | – |
-154,034
| Closed | -$2.16M |
|
86
Avalo Therapeutics
AVTX
$1.03B
| – | – |
-134,742
| Closed | -$2.01M |
|
87
CALL
Boston Scientific
BSX
$69.1B
| – | – |
-250,000
| Closed | -$12.5K |
|
88
Capricor Therapeutics
CAPR
$541M
| – | – |
-37,592
| Closed | -$1.14M |
|
89
Denali Therapeutics
DNLI
$3.55B
| – | – |
-426,561
| Closed | -$8.19M |
|
90
Dyne Therapeutics
DYN
$4.53B
| – | – |
-506,075
| Closed | -$9.18M |
|
91
CALL
Edwards Lifesciences
EW
$51.7B
| – | – |
-10,000
| Closed | -$1K |
|
|
92
Edwards Lifesciences
EW
$51.7B
| – | – |
-14,588
| Closed | -$1.17M |
|
93
Edgewise Therapeutics
EWTX
$4.54B
| – | – |
-290,864
| Closed | -$9.16M |
|
|
FBRX
94
DELISTED
Forte Biosciences
FBRX
| – | – |
-58,020
| Closed | -$1.5M |
|
95
Immunocore
IMCR
$1.9B
| – | – |
-63,543
| Closed | -$1.92M |
|
|
96
CALL
Immunovant
IMVT
$8.08B
| – | – |
-100,000
| Closed | -$255K |
|
97
Ionis Pharmaceuticals
IONS
$9.68B
| – | – |
-26,385
| Closed | -$1.98M |
|
98
Invivyd
IVVD
$237M
| – | – |
-1,874,546
| Closed | -$2.44M |
|
99
Johnson & Johnson
JNJ
$665B
| – | – |
-15,415
| Closed | -$3.77M |
|
100
Lipocine
LPCN
$20.1M
| – | – |
-160,420
| Closed | -$1.28M |
|
Similar funds
PM
CMA
RIS
GFI
CCWM
MFS
PWM
CA
Stempoint Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Stempoint Capital held 116 positions worth $581M, up 11% from $522M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Stempoint Capital withdrew a net $54.7M in Q2 2026, closing 32 positions and reducing 30 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $28.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Stempoint Capital opened a new position in First Tracks Biotherapeutics worth $12.5M.
- Stempoint Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 622,723 shares worth $12.5M.
- Stempoint Capital added most to Tango Therapeutics in Q2 2026, an estimated $25.3M increase.
- Stempoint Capital's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $38.5M.
- Stempoint Capital fully exited Syndax Pharmaceuticals in Q2 2026, selling an estimated $28.4M.
- Stempoint Capital's ten largest holdings make up 41% of its $581M portfolio in Q2 2026.
- Stempoint Capital opened 34 new positions and closed 32 in Q2 2026.
- Stempoint Capital's portfolio value rose 11% quarter-over-quarter to $581M.
Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.